Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)

Tipranks - Tipranks - Wed Apr 8, 5:54AM CDT

In a report released today, Trung Huynh from RBC Capital maintained a Sell rating on Pfizer, with a price target of $25.00.

Easter Sale - 70% Off TipRanks

Huynh covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Pfizer. According to TipRanks, Huynh has an average return of 27.1% and a 74.40% success rate on recommended stocks.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $29.02.

See the top stocks recommended by analysts >>

Based on Pfizer’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.56 billion and a GAAP net loss of $1.65 billion. In comparison, last year the company earned a revenue of $17.76 billion and had a net profit of $403 million

Read More on PFE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).